Formulation and device are one delivered-dose system. Every material attribute, component lot, assembly state, aerosol test, and release decision connected.

An inhalation product is released by the performance of a formulation–container–device system, not by bulk assay alone. Drug-particle or droplet properties, carrier and excipients, moisture, canister or blister, valve or dose-metering mechanism, actuator or inhaler geometry, filling and assembly, conditioning, patient-use sequence, and analytical apparatus jointly determine the dose reaching the lung.

Seal connects these states from raw material and device revision through manufacture, unit genealogy, delivered-dose and aerodynamic evidence, stability, investigations, and release.

Product type, API, strength, formulation, propellant or carrier, container, closure, valve, actuator, mouthpiece, dose counter, blister or capsule, inhaler body, metering mechanism, fill or unit dose, number of actuations, accessories, presentation, and market define the configuration.

Compatibility and effectivity prevent an approved formulation from being paired with an unsupported component revision.

API particle-size distribution, morphology, polymorph, surface area, density, electrostatics, water content, agglomeration, potency, impurity, excipient or carrier size and surface, propellant water, suspension properties, solution concentration, and microbiological state can affect delivery.

Supplier lots and test methods remain linked to the batches and device populations they enter.

Canister, valve, elastomer, spring, gasket, ferrule, actuator orifice, dose counter, blister foil, capsule, inhaler reservoir, mesh or nebulizer interface retain supplier, site, material, tooling or cavity, dimensions, treatments, cleaning, lubrication, extractables, specification, inspection, lot, and revision.

Component genealogy reaches individual or bounded finished-unit populations where risk requires it.

Order of addition, mixing, homogenization, milling, sonication, temperature, pressure, moisture and humidity, hold, agitation, recirculation, suspension uniformity, particle growth, dissolution, bioburden, and sampling define the bulk process.

Seal preserves the relationship between process time and the filled-unit population when suspension settling or other time effects matter.

Cold fill or pressure fill, concentrate and propellant, fill weights, valve placement, crimp dimensions, canister pressure, leak check, headspace, shaking, filling head, crimp station, rejects, interventions, and reconciliation establish unit state.

The record can identify units affected by a valve lot, filling interval, head, crimp tool, or pressure excursion.

Blend or engineered particle supply, environmental humidity, dose metering, capsule or blister fill, reservoir charge, sealing, inhaler assembly, component orientation, torque or snap, dose-counter engagement, line speed, rejects, and cleaning state define the DPI population.

Low-dose material balance and line carryover remain reconciled across bulk, filled doses, samples, dust extraction, rejects, and recovery.

Solution or suspension preparation, sterilizing filtration or terminal sterilization where applicable, blow-fill-seal or ampoule filling, container closure, fill volume, overwrap, microbial controls, visible particles, delivered volume, nebulizer compatibility, droplet size, and administration time connect to the product claim.

The intended nebulizer or device family and operating conditions remain part of performance evidence.

Priming, shaking, orientation, storage, equilibration, environmental condition, valve or mechanism settling, initial actuations, dose counter state, cleaning or preparation, and time before test can affect results.

Laboratory and stability samples retain exact conditioning rather than relying on tacit analyst technique.

Beginning, middle and end of container life; primed, reprimed and unprimed states; flow rate; pressure drop; actuation timing; shake and wait; collection apparatus; dose number; cleaning; sample sequence; and recovery define the test.

Each actuation and reported stage value links to the unit, product configuration, method version, source data, calculations, exclusions, and review.

Cascade impactor or impinger, throat and induction port, stages, cups, coatings, flow, duration, pressure drop, leak check, environmental state, recovery, assay, stage cutoffs, calculations, fine-particle dose or fraction, mass median aerodynamic diameter, geometric standard deviation, and mass balance form the result.

Raw stage data remain visible beneath derived metrics.

Spray pattern, plume geometry, droplet size, velocity, priming, actuator geometry, orifice, laser diffraction, imaging, morphology, dissolution, emitted particle size, electrostatics, and device resistance may support development, comparability, investigations, and control.

Their intended use and relationship to product performance remain explicit.

Actuation force, lockout, dose-counter accuracy, tail-off, resistance, flow dependency, robustness, drop or vibration, temperature, leakage, valve delivery, number of doses, incomplete actuation, cleaning, misuse, human factors, and accessory compatibility connect to product configuration and sample.

Pharmaceutical and device deviations converge in the same finished-unit history.

Chromatograms, impactor worksheets or electronic files, balance data, flow calibration, environmental readings, instrument methods, images, integration, stage calculations, sample preparation, standards, suitability, audit trails, repeats, and exclusions remain preserved.

Seal contextualizes SDMS evidence against units, actuations, apparatus configuration, and claims.

Batches, configurations, orientations, conditions, moisture barrier, overwrap, timepoints, unit conditioning, assay, degradation, moisture, delivered dose, APSD, leak or pressure, valve or device function, appearance, microbial quality, extractables and leachables, and use-life results remain connected.

Trends can separate formulation aging from device or packaging drift.

Low delivered dose, APSD shift, high variability, poor recovery, leak, valve sticking, blocked orifice, incomplete actuation, dose-counter error, capsule retention, blister issue, moisture ingress, apparatus leak, analyst technique, integration, or standard issue follows OOS and device-investigation logic.

Impact traverses sibling units, component lots, filling or assembly windows, batches, stability pulls, methods, devices, markets, and distributed populations.

API or carrier source, particle attributes, formulation, propellant, component material or dimension, supplier site, tooling, valve, actuator, device, fill process, assembly, package, overwrap, cleaning, analytical apparatus, method, software, manufacturing site, or patient instruction change can affect performance.

Impact identifies development, E&L, compatibility, analytical bridging, device verification, process validation, stability, human factors, bioequivalence, filing, and inventory transition.

Materials, bulk process, filling or dose metering, components, line and tooling, unit genealogy, reconciliation, in-process controls, delivered dose, APSD and other specifications, device function, deviations, stability commitments, market configuration, and approvals form release.

Passing bulk chemistry cannot override failed aerosol delivery.

Seal is strongest across material science, device components, MES, laboratories, SDMS, stability, combination-product quality, suppliers, change control, regulatory, and release. It owns the configuration and unit-to-performance relationship across those systems.

The first implementation should follow a suspension MDI through API particle attributes, formulation and hold, canister and valve lots, pressure filling, crimp stations, leak checks, unit conditioning, beginning-middle-end delivered dose, cascade impaction, device functionality, stability, an OOS cluster, investigation, actuator change, bridging, and release.

Include suspension settling, one filling-head excursion, valve-lot dimensional drift, impactor leak failure, low recovery, dose-counter mismatch, moisture trend, an unbracketed actuator, and market-specific presentation. The system must identify the exact units and claim affected by each signal.